Commercial and Pipeline Insight - Fibromyalgia - Approvals legitimize condition and expose underserved patient population - www.companiesandmarkets.com adds new report

2008-08-12 11:19:02 - Commercial and Pipeline Insight - Fibromyalgia - Approvals legitimize condition and expose underserved patient population - a new market research report on www.companiesandmarkets.com

Introduction

With a considerable patient potential and large medical unmet need, the untapped fibromyalgia market represents a lucrative opportunity for pharmaceutical companies. Estimated to total around $650m in 2007 in the seven major markets, forecasts show the market to grow to over $2.4 billion in 2017.

Scope

*Analysis of clinical trial design and treatment guidelines in fibromyalgia.

*Fibromyalgia market sizing assessment with detailed methodology.

*Detailed

 

 

profiles of key late-stage pipeline products for fibromyalgia, with indication-specific forecasts to 2017.

*Case study analysis of Pfizer´s launch strategy for Lyrica (pregabalin) as well as assessment of development timeline.

Highlights

The approval of Pfizer´s Lyrica transformed the previously unchartered fibromyalgia market and provided a new level of validity for this disputed condition.

In June 2008, Eli Lilly´s dual serotonin and norepinephrine reuptake inhibitor (SNRI) Cymbalta (duloxetine) became the second FDA approved fibromyalgia treatment. Seven major market Cymbalta sales for fibromyalgia to peak at in excess of half a billion US dollars in 2012 prior to US and EU patent expiries.

As has been successful for Pfizer, televised direct-to-consumer (DTC) drug advertising campaigns will continue to be an important marketing tool for new players, providing a boost to sales and adding further legitimacy to the condition.

Reasons to Purchase

*Understand the current fibromyalgia market dynamics and how they are expected to evolve out to 2017.

*Benchmark key late-stage pipeline fibromyalgia compounds against the current market leading brand, supported by insight from key opinion leaders.

*Assess seven major market sales forecasts of marketed and key late-stage pipeline fibromyalgia drugs.


www.companiesandmarkets.com/Summary-Market-Report/Commercial-and ..